pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-124-1 |
Genomic Coordinates | chr8: 9903388 - 9903472 |
Description | Homo sapiens miR-124-1 stem-loop |
Comment | miR-124 was first identified by cloning studies in mouse . The 5' end of the miRNA may be offset with respect to previous annotations. |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
pre-miRNA | hsa-mir-124-2 |
Genomic Coordinates | chr8: 64379149 - 64379257 |
Description | Homo sapiens miR-124-2 stem-loop |
Comment | miR-124 was first identified by cloning studies in mouse . The 5' end of the miRNA may be offset with respect to previous annotations. |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
pre-miRNA | hsa-mir-124-3 |
Genomic Coordinates | chr20: 63178500 - 63178586 |
Description | Homo sapiens miR-124-3 stem-loop |
Comment | miR-124 was first identified by cloning studies in mouse . The 5' end of the miRNA may be offset with respect to previous annotations. |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-124-5p | ||||||||||||||||||||||||||||||
Sequence | 14| CGUGUUCACAGCGGACCUUGAU |35 | ||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | USP32 | ||||||||||||||||||||
Synonyms | NY-REN-60, USP10 | ||||||||||||||||||||
Description | ubiquitin specific peptidase 32 | ||||||||||||||||||||
Transcript | NM_032582 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on USP32 | |||||||||||||||||||||
3'UTR of USP32 (miRNA target sites are highlighted) |
>USP32|NM_032582|3'UTR 1 AGCTACCACTCTGGCTGCTAGACAGCTTGGCGGTGAGGGAGATGACTCCTTGTAGCTGACATTTGGCAAAAGCGTCACTG 81 AAAGGCAAGCTAAATGTAGTTATTTTATCCTGTGGCCCTGAAGCACAAAATAAAAATTCTAATTAAAATAGTTAACTTTA 161 AGAGTAGTAATCATTTTATTTTGAAGTCTCATACAAGCTCTCCGATAGAGAACTTTCAGGCAGATCCCACCATTAGCCTG 241 TAAACAAAAGGTTTGGCACCAGCCACCTGGGACCAAATAAGAATTCAATTGTGCTTGTCCAGATATGAACAAATATGTAG 321 TGAGTATAGAGTTTACCATAATCATAACAAATATTAAAGATTTCCTTGGAGTCAGAGTAAAAAACAAACAATTATAATGT 401 TGTCTAGGGACGACATGATATGCTACCTCCTTTTTCCTGAAGTTTTATTCCATTATATTGACAAGATGGAGAAAGCAAGA 481 TCACGAAGGTGTGCAAATGATTCTTAAGGCATGGACGAGGATTTTTCAATTTATTTTTTAAACTGTTTCCATACCCTTTC 561 TTTGTCTTTCTTGCTTTTTGTTTTTGCCGTTGTATTTATGTTTGAGACACAACCAGTCATTGGTGGCAGGGGCATATAGT 641 GGTCAGTCTGAAAGGGAGGCTCTCTTAAGAGCTGTGTGCCTTCCACCCAGAGCCTTGTGGGAGACCCAGTAGAAAGAAAC 721 AGCATCCTGGGAAATCCAGCTACCATGGCCCTCCCAGTGGAGGCATCTTACATTTAGGATACTTCAAGTATCCTCAGAAA 801 TGTATTCTGCACCCCCGGCCCCACCCATGCTGAGGGAAGGGGAGCAGTTGCCAATATTTGCACCATCTTCACATGCACCT 881 GTTGCAACAAGAGCTTCTGGGAAGGTAAGTGGCATTGGAGCTAGATCACGTTTCACAATTAGTGGTTGTTCTTTTCTGTG 961 TTTGTCTTGCACTTTAAAAAAGAGAGAACACATGCAAATGAACTTGCTTGTGTGTATTTGATGGCTCTAAGGGCTATAAA 1041 TTACAAACAAAACACATCCCAGACATTAGGAGTTCATAAGTGTATTTAATGAAATTGGTGGTTTTAGGAAGTCAACTTTA 1121 GTTTTGCTTTGTTTGCATGTCCACTAATTTTTTTATTTTGATATTTGTCTTTTTTTTAAATTTTACAGTAGTCATCGAAA 1201 GTTATGTTTCTTTGCTTACTTCATTTTTTTCTCTAATCAAGACTGGAACAAAAGTATAAATATTATTTATTTCAGGTAGC 1281 ATTTTTTTCGTGTAGTTTTTTAATATATACTTGAAGGAAATGTTTCACCTTATTTTTGGTCTTTGTTTATTCATTTAGAC 1361 CCTGCAAGTTGATTCTCATTAATTGTCAGATTCCACTACCCTTTCTTCCTCATAGATAGTAATTACCAATGTAACTAAGT 1441 ATTTGTGTTCTGATATCTGAGGCCAGTAACTATTAATATCTAGTTCTCAGAGCATTTGGAAAGGTTATCTTAAATGGCTA 1521 CCTAAATTGAAATCCTTTTCAGAAAAAATATAATTGCAAGTAGGTAGGACTGGCCTAAATTGTCTAATGTAATAAAGTCA 1601 GACAAAATGCATACTTTATAGTTTCAAGATTTTCAGTATATAAAATCTGTCCATTCCCATTAAAAAGTGGAAGATTTTAA 1681 ATAATTTCTTTACAGATGTTTTATTTAAGCAGGTAGCTCAATCTACTAATGTTGTTTGATCTGTGTTTGTTATACTGGTT 1761 GTAATTAATTTTTTTAATTCATGAACTAGCAGAAAATTTATTAAATTAACTATTAACTACATTCACCTTGTAAATTACTG 1841 TATAAAACTTGTTGACAATGCACTGACTTTAGAAAGATGTTAATGTACATAAATAGAGTGTAAATAAAATAGTGTTGATG 1921 TACCG Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084066. RNA binding protein: AGO2. Condition:CLIP_noemetine_SantaCruzAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
CLIP-seq Support 1 for dataset GSM1084066 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_noemetine_SantaCruzAb |
Location of target site | ENST00000300896.4 | 3UTR | UUGUCUUGCACUUUAAAAAAGAGAGAAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
65 hsa-miR-124-5p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT064177 | KIAA1804 | mitogen-activated protein kinase kinase kinase 21 | ![]() |
![]() |
2 | 2 | ||||||
MIRT069736 | FOXG1 | forkhead box G1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT086429 | NABP1 | nucleic acid binding protein 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT105334 | SLC7A2 | solute carrier family 7 member 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT110455 | PLEKHA1 | pleckstrin homology domain containing A1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT172998 | YTHDF3 | YTH N6-methyladenosine RNA binding protein 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT196428 | TAOK1 | TAO kinase 1 | ![]() |
![]() |
2 | 14 | ||||||
MIRT325704 | CSTF2 | cleavage stimulation factor subunit 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT365670 | TSC22D3 | TSC22 domain family member 3 | ![]() |
![]() |
2 | 4 | ||||||
MIRT365873 | XIAP | X-linked inhibitor of apoptosis | ![]() |
![]() |
2 | 2 | ||||||
MIRT404126 | ASB1 | ankyrin repeat and SOCS box containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT404626 | LCOR | ligand dependent nuclear receptor corepressor | ![]() |
![]() |
2 | 2 | ||||||
MIRT405284 | ARF1 | ADP ribosylation factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT406099 | PAGR1 | PAXIP1 associated glutamate rich protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446627 | SDC3 | syndecan 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446906 | RGS5 | regulator of G protein signaling 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT461790 | FXR2 | FMR1 autosomal homolog 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT463982 | WEE1 | WEE1 G2 checkpoint kinase | ![]() |
![]() |
2 | 4 | ||||||
MIRT464204 | VGLL4 | vestigial like family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT472790 | MTMR4 | myotubularin related protein 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT473485 | MCFD2 | multiple coagulation factor deficiency 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT481124 | AZIN1 | antizyme inhibitor 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT485060 | SUCO | SUN domain containing ossification factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT487343 | HLA-DRA | major histocompatibility complex, class II, DR alpha | ![]() |
![]() |
2 | 2 | ||||||
MIRT491948 | VPS52 | VPS52, GARP complex subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT497208 | CDH7 | cadherin 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT497476 | TOR1AIP2 | torsin 1A interacting protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT528203 | NELFE | negative elongation factor complex member E | ![]() |
![]() |
2 | 2 | ||||||
MIRT529255 | TRIM4 | tripartite motif containing 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT530096 | PSAPL1 | prosaposin like 1 (gene/pseudogene) | ![]() |
![]() |
2 | 2 | ||||||
MIRT530597 | C7orf33 | chromosome 7 open reading frame 33 | ![]() |
![]() |
2 | 4 | ||||||
MIRT534980 | PSAT1 | phosphoserine aminotransferase 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT538326 | CSGALNACT1 | chondroitin sulfate N-acetylgalactosaminyltransferase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT561237 | ZNF652 | zinc finger protein 652 | ![]() |
![]() |
2 | 2 | ||||||
MIRT562035 | KRAS | KRAS proto-oncogene, GTPase | ![]() |
![]() |
2 | 2 | ||||||
MIRT563120 | THAP5 | THAP domain containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT563538 | RBM41 | RNA binding motif protein 41 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566037 | REV3L | REV3 like, DNA directed polymerase zeta catalytic subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT566505 | PAWR | pro-apoptotic WT1 regulator | ![]() |
![]() |
2 | 2 | ||||||
MIRT566745 | MRPL35 | mitochondrial ribosomal protein L35 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566850 | LRRC58 | leucine rich repeat containing 58 | ![]() |
![]() |
2 | 2 | ||||||
MIRT568077 | CELF2 | CUGBP Elav-like family member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT576826 | Tgfbr3 | transforming growth factor, beta receptor III | ![]() |
![]() |
2 | 2 | ||||||
MIRT608870 | NR2E1 | nuclear receptor subfamily 2 group E member 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT611997 | VAC14 | Vac14, PIKFYVE complex component | ![]() |
![]() |
2 | 2 | ||||||
MIRT614054 | FAM89A | family with sequence similarity 89 member A | ![]() |
![]() |
2 | 2 | ||||||
MIRT618800 | SPATA21 | spermatogenesis associated 21 | ![]() |
![]() |
2 | 2 | ||||||
MIRT619389 | RSPH3 | radial spoke head 3 homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT622282 | SH3TC2 | SH3 domain and tetratricopeptide repeats 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT624026 | EN2 | engrailed homeobox 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT626000 | MPEG1 | macrophage expressed 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT641792 | USP32 | ubiquitin specific peptidase 32 | ![]() |
![]() |
2 | 2 | ||||||
MIRT651599 | WDFY2 | WD repeat and FYVE domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT659662 | CDC73 | cell division cycle 73 | ![]() |
![]() |
2 | 2 | ||||||
MIRT663010 | KIAA1586 | KIAA1586 | ![]() |
![]() |
2 | 2 | ||||||
MIRT663561 | ASTN2 | astrotactin 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT669312 | C16orf72 | chromosome 16 open reading frame 72 | ![]() |
![]() |
2 | 2 | ||||||
MIRT685216 | POTED | POTE ankyrin domain family member D | ![]() |
![]() |
2 | 2 | ||||||
MIRT695757 | ZNF117 | zinc finger protein 117 | ![]() |
![]() |
2 | 2 | ||||||
MIRT697909 | TXNRD1 | thioredoxin reductase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT707181 | RPH3A | rabphilin 3A | ![]() |
![]() |
2 | 2 | ||||||
MIRT707214 | TRIM13 | tripartite motif containing 13 | ![]() |
![]() |
2 | 2 | ||||||
MIRT707478 | SLCO4C1 | solute carrier organic anion transporter family member 4C1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT719507 | LMAN2L | lectin, mannose binding 2 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT755814 | PARP1 | poly(ADP-ribose) polymerase 1 | 2 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|